3 Reasons to Avoid SUPN and 1 Stock to Buy Instead

Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3% gain. This might have investors contemplating their next move.